Risikoadaptierte multimodale gynäkozytologische Krebsvorsorge

Bollmann, R.; Varnai, A.; Bànkfalvi, Àgnes; Bollmann, Magdolna

doi:10.1007/s00292-007-0923-9

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Следовательно, методы жидкостной цитологии (автоматизированные технологии) обеспечивают оптимальную платформу для риск-адаптированной многомодальной профилактики гинекологического рака с высокой PPV. А при одновременном проведении генотипирования ВПч можно достичь PPV, равной 88,2%, для цервикальной дисплазии и карциномы средней и высокой степени (≥ цервикальной интраэпителиальной неоплазии ii) [9]. В современной литературе не описаны методы, позволяющие достичь более высокой PPV.…”

Section: жидкостная цитология в качестве платформы для молекулярного unclassified

Liquid-based cytology for risk-adapted cervical screening

Bollmann¹

2015

Reproductive Endocrinology

View full text Add to dashboard Cite

Jan dolezil Гамбург, Германия * статья опубликована в журнале Gynakol Geburtsmed Gynakol Endokrinol 4(2) (2008): 164-180 ТАблИцА 1. ПреИМУщеСТВА И недОСТАТкИ МеТОдА жИдкОСТнОй цИТОлОГИИ-АВТОМАТИзИрОВАнные ТехнОлОГИИ Преимущества недостатки Передплата на журнал 330 грн Дата здійснення операції «___»___________20__ р. Підпис платника ___________ Підпис банку ___________

show abstract

Section: жидкостная цитология в качестве платформы для молекулярного unclassified

Liquid-based cytology for risk-adapted cervical screening

Bollmann¹

2015

Reproductive Endocrinology

View full text Add to dashboard Cite

show abstract

“…Ein Beispiel daf ü r ist der PAP-Test, der zur Fr ü herkennung des Geb ä rmutterhalstumors verwendet und als Kassenleistung angeboten wird. Daneben gibt es eine verbesserte Screening-M ö glichkeit mit dem HPV-Test, die dem gesetzlich versicherten Patienten in der Regel nicht als Kassenleistung zur Verf ü gung steht[11] . Nur wenn ein verd ä chtiges Ergebnis der zytologischen Untersuchung (Pap III oder IIID) abgekl ä rt werden soll, ü bernimmt die GKV die Kosten (EBM: 32820).…”

unclassified

Ärztliche Dienstleistung: eine Zufriedenheitsbefragung bei Patienten und niedergelassenen Ärzten

Weisenfeld¹,

Sorensen²,

Scherer³

2009

Gesundheitswesen

View full text Add to dashboard Cite

In 2007, the German health-care system was once again subject to reform. Demographic changes and a rising demand for health-care services on the one hand and technological progress with increased medical-technological possibilities on the other lead to questions about organising and financing health care. Moreover, with the German health care being a mixture of a public insurance systems and private insurances, the extent, quality and equality of access is constantly under debate. In an empirical study, 1 604 patients were asked about their satisfaction with medical services and their insurance as well as their views on the recent reform. 90 physicians were questioned about their job satisfaction and their views on the health care system and the recent reform. Patients, irrespective of their type of insurance, on average were very satisfied with the physicians' services. Privately insured patients on average were more satisfied with their insurance than publicly insured. Patients were not well informed about the reform. Physicians' job satisfaction was markedly lower, they anticipate problems with health-care provision and they judge the health-care reform as inappropriate. Thus, patients on average are very satisfied with medical services, physicians on average are not satisfied with their situation, and the health-care reform is not perceived as a great success.

show abstract

Performance of a Polymer-Based DNA Chip Platform in Detection and Genotyping of Human Papillomavirus in Clinical Samples

et al. 2009

View full text Add to dashboard Cite

Human papillomavirus (HPV) plays a key role in the development of cervical and laryngeal cancers. The aim of our study was to compare the performance of a new hydrogel-based HPV genotyping biochip assay (Biochip) to a commercially available and CE-marked conventional PCR followed by reverse hybridization (GenID-PCR). One hundred twenty-three samples were available for the study. Of these samples, 101/123 were gynecological swabs, 8/123 were swabs or biopsy samples of genital warts, 7/123 were biopsy samples of otorhinolaryngeal lesions, 5/123 were samples of skin warts, and 2/123 were samples of orolabial abnormalities. These molecular methods for HPV genotyping showed comparable sensitivity and specificity. However, 19/123 of the results were discrepant. Specifically, Biochip showed better performance in the detection of multiple infections, especially when more than one high-risk genotype was present. Due to the different probe configurations used in the two assays, GenID-PCR achieves only group-specific detection of many HPV genotypes, whereas Biochip allows for specific identification. Overall, the newly developed HPV chip system (Biochip) proved to be a suitable tool for HPV detection and genotyping; it also proved to be superior for establishing HPV genotyping methods.Persistent infection with human papillomavirus (HPV) is now well known to play the key role in the development of cervical carcinoma, which is the second most common malignancy in women worldwide. Certain HPV genotypes have been shown to be associated with a high risk for carcinogenesis. HPV type 16 (HPV-16) and HPV-18 are responsible for more than 70% of cervical carcinomas, whereas other high-risk genotypes (HPV-31, -33, -45, -52, -58, and others) are found less frequently (34,38,39).Due to the high negative predictive value of a negative HPV test result combined with negative cytology results, it is expected that, in the future, DNA testing will complement cytology in routine gynecological screening, thus enabling the development of a more cost-efficient screening program with expanded intervals between patient visits (11). For women with low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance, HPV testing is an important requirement for triage strategies (3, 32). Since a significant proportion of HPV infections, including high-risk genotypes HPV-16 and -18, are cleared within several months by the immune system, single detection of HPV DNA alone is not sufficient to predict cancer development, especially in younger women (5). Consequently, the ability to genotype at least the most common high-risk HPV strains, i.e., and -18, in order to distinguish persistent infections with the same genotype from subsequent infections with other HPV genotypes is an important feature of modern HPV assays (16,33).In the last 2 years, we have seen a breakthrough in the prevention of HPV infections. Much of the progress is the result of immunological studies that have paved the way for development of the first effe...

show abstract

Risikoadaptierte multimodale gynäkozytologische Krebsvorsorge

Cited by 3 publications

References 32 publications

Liquid-based cytology for risk-adapted cervical screening

Liquid-based cytology for risk-adapted cervical screening

Ärztliche Dienstleistung: eine Zufriedenheitsbefragung bei Patienten und niedergelassenen Ärzten

Performance of a Polymer-Based DNA Chip Platform in Detection and Genotyping of Human Papillomavirus in Clinical Samples

Contact Info

Product

Resources

About